Evidence map›Paper›PMID 37331337›Full record

ReviewAudiology & neuro-otology2023

Genotype-Phenotype Correlations in TMPRSS3 (DFNB10/DFNB8) with Emphasis on Natural History.

Eric Nisenbaum, Denise Yan, A Eliot Shearer, Evan de Joya, Torin Thielhelm, Nicole Russell, Hinrich Staecker, Zhengyi Chen, Jeffrey R Holt, Xuezhong Liu

Open access · greenAbstract readReview
In one paragraph

Review in Audiology & neuro-otology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Novel splice-site variants inFrontiers in genetics · 2026
    Article
  2. ADPKD Progression by Variant Type and Molecular Domain Among Participants in the HALT PKD Trial.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  3. Article
  4. Article
  5. [Late-onset hereditary hearing loss caused byLin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Eric NisenbaumDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA, eric.nisenbaum@jhsmiami.org.
Denise YanDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.
A Eliot ShearerDepartment of Otolaryngology-Head and Neck Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Evan de JoyaDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Torin ThielhelmDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Nicole RussellDepartment of Otolaryngology-Head and Neck Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Hinrich StaeckerDepartment of Otolaryngology Head and Neck Surgery, University of Kansas Health System, Kansas City, Kansas, USA.
Zhengyi ChenDepartment of Otolaryngology and Program in Neuroscience, Harvard Medical School and Eaton Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Jeffrey R HoltDepartment of Otolaryngology-Head and Neck Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Xuezhong LiuDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.
University of Miami · USBoston Children's Hospital · USMassachusetts Eye and Ear Infirmary · USThe University of Kansas Health System · US

Funding

Molecular Genetics on Non Syndromic Hearing Loss (NSHL)R01DC005575 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, XUE Z · 2001 to 2024
$10.6M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
Sensory disorders in COVID -19 as an early identifier and healthcare worker protectionR01DC012115 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, XUE Z · 2013 to 2022
$7.2M
Interdisciplinary Research Training in OtolaryngologyT32DC015995 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, XUE Z · 2018 to 2022
$330k
NICHD NIH HHS P50 HD105351NIDCD NIH HHS R01 DC005575NIDCD NIH HHS R01 DC012115NIDCD NIH HHS T32 DC015995
6 · The paper itself

Abstract

backgroundMutations in TMPRSS3 are an important cause of autosomal recessive non-syndromic hearing loss. The hearing loss associated with mutations in TMPRSS3 is characterized by phenotypic heterogeneity, ranging from mild to profound hearing loss, and is generally progressive. Clinical presentation and natural history of TMPRSS3 mutations vary significantly based on the location and type of mutation in the gene. Understanding these genotype-phenotype relationships and associated natural disease histories is necessary for the successful development and application of gene-based therapies and precision medicine approaches to DFNB8/10. The heterogeneous presentation of TMPRSS3-associated disease makes it difficult to identify patients clinically. As the body of literature on TMPRSS3-associated deafness grows, there is need for better categorization of the hearing phenotypes associated with specific mutations in the gene. SUMMARY: In this review, we summarize TMPRSS3 genotype-phenotype relationships including a thorough description of the natural history of patients with TMPRSS3-associated hearing loss to lay the groundwork for the future of TMPRSS3 treatment using molecular therapy. KEY MESSAGES: TMPRSS3 mutation is a significant cause of genetic hearing loss. All patients with TMPRSS3 mutation display severe-to-profound prelingual (DFNB10) or a postlingual (DFNB8) progressive sensorineural hearing loss. Importantly, TMPRSS3 mutations have not been associated with middle ear or vestibular deficits. The c.916G>A (p.Ala306Thr) missense mutation is the most frequently reported mutation across populations and should be further explored as a target for molecular therapy.

Indexed as

Hearing LossHearing Loss, SensorineuralGenetic Association StudiesHumansMembrane ProteinsMutationNeoplasm ProteinsPhenotypeSerine EndopeptidasesMembrane ProteinsNeoplasm ProteinsSerine EndopeptidasesTMPRSS3 protein, humanAutosomal recessive non-syndromic hearing lossGene therapyGenetic diseaseGenotype-phenotype correlationHearing loss

Identifiers

PMID37331337
PMCPMC10857012
OpenAlexW4381158186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.